Humira Revenue Up 9.6% In U.S., But Down Abroad Due To Biosimilar IN CASE YOU MISSED IT: The poster child for how big, brand-name drug companies abuse the patent system to keep drug prices high continues to reap the benefits from gaming the U.S. patent system. Yesterday, Inside Health Policy reported that Abbvie’s revenue from Humira […]

Continue Reading

WHAT YOU NEED TO KNOW This Wednesday, the Senate Judiciary Subcommittee on Intellectual Property held a hearing on the need to strengthen patent quality and prevent the spread of low-quality and invalid patents, which have contributed in part to high drug prices. CAPA released a statement commending Sen. Tillis (R-NC) for holding this hearing and […]

Continue Reading